Pembrolizumab Enhances the Anti-Leukemia Activity of Antigen Specific Cytotoxic T Lymphocytes

Authors

• Zara Italia, The University of Texas MD Anderson Cancer CenterFollow
• Kathleen Ready, The University of Texas MD Anderson Cancer CenterFollow
• Mao Zhang, The University of Texas MD Anderson Cancer Center
• Maria R. Khouri, The University of Texas MD Anderson Cancer Center
• Pariya Sukhumalchandra, The University of Texas MD Anderson Cancer Center
• Anne V. Phillips, The University of Texas MD Anderson Cancer Center
• Na Qiao, The University of Texas MD Anderson Cancer Center
• Celine Kerros, The University of Texas MD Anderson Cancer Center
• Lisa St. John, The University of Texas MD Anderson Cancer Center
• Alexander A. Perakis, The University of Texas MD Anderson Cancer Center
• Daniel Ghaisariee, The University of Texas MD Anderson Cancer Center
• Karen Clise-Dwyer, The University of Texas MD Anderson Cancer Center
• Elizabeth Mittendorf, Dana-Farber/Brigham and Women’s Cancer Center
• Naval G. Daver, The University of Texas MD Anderson Cancer Center
• Jeffrey J. Molldrem, The University of Texas MD Anderson Cancer CenterFollow
• Qing Ma, The University of Texas MD Anderson Cancer Center
• Gheath Alatrash, The University of Texas MD Anderson Cancer Center

Files

Program Affiliation

UPWARDS Summer Program

Recommended Citation

Italia, Zara; Ready, Kathleen; Zhang, Mao; Khouri, Maria R.; Sukhumalchandra, Pariya; Phillips, Anne V.; Qiao, Na; Kerros, Celine; St. John, Lisa; Perakis, Alexander A.; Ghaisariee, Daniel; Clise-Dwyer, Karen; Mittendorf, Elizabeth; Daver, Naval G.; Molldrem, Jeffrey J.; Ma, Qing; and Alatrash, Gheath, "Pembrolizumab Enhances the Anti-Leukemia Activity of Antigen Specific Cytotoxic T Lymphocytes" (2023). Summer Experience 2023. 69.
https://openworks.mdanderson.org/sumexp23/69

Keywords

Acute Myeloid Leukemia; Pembrolizumab; Cytotoxic T Lymphocytes; PR1 Antigen Specific CTL; CG1 Antigen Specific CTL